Interchangeable Insulins - New Pathways for Safe, Effective, Affordable Diabetes Therapy.
作者信息
Socal Mariana P, Greene Jeremy A
机构信息
From the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health (M.P.S.), and the Department of History of Medicine and the Center for Medical Humanities and Social Medicine, Johns Hopkins University School of Medicine (J.A.G.) - both in Baltimore.
出版信息
N Engl J Med. 2020 Mar 12;382(11):981-983. doi: 10.1056/NEJMp1916387.
PMID:32160658
Abstract
摘要
相似文献
1
Interchangeable Insulins - New Pathways for Safe, Effective, Affordable Diabetes Therapy.可互换胰岛素——安全、有效、可负担得起的糖尿病治疗新途径。
N Engl J Med. 2020 Mar 12;382(11):981-983. doi: 10.1056/NEJMp1916387.
2
New Insulins, Biosimilars, and Insulin Therapy.新型胰岛素、生物类似药与胰岛素治疗
Diabetes Technol Ther. 2018 Feb;20(S1):S55-S70. doi: 10.1089/dia.2018.2505.
3
New Insulins, Biosimilars, and Insulin Therapy.新型胰岛素、生物类似药与胰岛素治疗
Diabetes Technol Ther. 2017 Feb;19(S1):S42-S58. doi: 10.1089/dia.2017.2505.
4
New Insulins, Biosimilars, and Insulin Therapy.新型胰岛素、生物类似药与胰岛素治疗
Diabetes Technol Ther. 2020 Feb;22(S1):S32-S46. doi: 10.1089/dia.2020.2503.
5
Biosimilar insulins are coming: what they are, what you need to know.生物类似物胰岛素即将问世：它们是什么，你需要了解什么。
Curr Med Res Opin. 2014 Nov;30(11):2217-22. doi: 10.1185/03007995.2014.952718. Epub 2014 Aug 20.
6
New Insulins, Biosimilars, and Insulin Therapy.新型胰岛素、生物类似药与胰岛素治疗
Diabetes Technol Ther. 2019 Feb;21(S1):S57-S78. doi: 10.1089/dia.2019.2505.
7
Introduction of biosimilar insulins in Europe.欧洲的生物类似胰岛素介绍。
Diabet Med. 2017 Oct;34(10):1340-1353. doi: 10.1111/dme.13400. Epub 2017 Jul 16.
8
The Cost-Effectiveness of Intermediate-Acting, Long-Acting, Ultralong-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: A Systematic Review.1 型糖尿病中效、长效、超长效及生物类似胰岛素的成本-效果分析：系统评价
Value Health. 2022 Jul;25(7):1235-1252. doi: 10.1016/j.jval.2021.12.016. Epub 2022 Mar 24.
9
New Insulins, Biosimilars, and Insulin Therapy.新型胰岛素、生物类似药与胰岛素治疗
Diabetes Technol Ther. 2021 Jun;23(S2):S46-S68. doi: 10.1089/dia.2021.2504.
10
New Insulins, Biosimilars, and Insulin Therapy.新型胰岛素、生物类似药与胰岛素治疗
Diabetes Technol Ther. 2023 Feb;25(S1):S44-S69. doi: 10.1089/dia.2023.2504.
引用本文的文献
1
Lessons From Insulin: Policy Prescriptions for Affordable Diabetes and Obesity Medications.从胰岛素中吸取的教训：制定负担得起的糖尿病和肥胖症药物的政策处方。
Diabetes Care. 2024 Aug 1;47(8):1246-1256. doi: 10.2337/dci23-0042.
2
Patent "Evergreening" of Medicine-Device Combination Products: A Global Perspective.药品-器械组合产品的专利“常青化”：全球视角。
Healthc Policy. 2022 Oct;18(2):14-26. doi: 10.12927/hcpol.2022.26973.
3
Bipartisan Federal Legislation to Address Insulin Access and Affordability.两党联合提出的解决胰岛素可及性和可负担性问题的联邦立法。
Diabetes Spectr. 2021 Nov;34(4):394-398. doi: 10.2337/ds21-0008. Epub 2021 Jun 30.
4
Rapid quantification of insulin degludec by immunopurification combined with liquid chromatography high-resolution mass spectrometry.免疫纯化结合液相色谱-高分辨质谱快速定量德谷胰岛素。
Anal Bioanal Chem. 2020 Dec;412(30):8351-8359. doi: 10.1007/s00216-020-02971-4. Epub 2020 Oct 2.
Zotero 插件